may offer rapid symptom relief for , but the evidence is still developing.
Evidence
This review analyzed clinical studies from 2014 to 2024 on psilocybin for MDD, alone or with psychotherapy, covering efficacy, safety, mechanisms, and regulatory barriers.
Caveat
The abstract emphasizes Schedule I restrictions, societal stigma, and the need for larger, more diverse studies with long-term safety and efficacy data.
Simplified
, a naturally occurring psychedelic compound, has received attention as a novel therapeutic option for (MDD), particularly in cases where traditional treatments prove ineffective. The study aims to evaluate psilocybin's therapeutic potential by examining its efficacy, safety, and mechanisms of action as well as addressing the societal and regulatory challenges that hinder its broader application. Key objectives include understanding how psilocybin alleviates depressive symptoms, investigating its neurobiological effects, and identifying gaps in current research. The methodology involved analyzing clinical studies conducted between 2014 and 2024, focusing on psilocybin as an intervention, either independently or in conjunction with psychotherapy. Evidence from these studies demonstrates that psilocybin acts on serotonin 5-HT2A receptors, enhancing neuroplasticity and brain connectivity to yield rapid and sustained symptom relief. Despite these promising findings, the use and study of psilocybin remains restricted due to its classification as a Schedule I substance in many countries. Legal prohibitions and societal stigma have significantly delayed progress in exploring psilocybin's therapeutic applications. The findings highlight psilocybin's potential to transform MDD treatment paradigms but emphasize the need to overcome regulatory barriers, conduct larger and more diverse studies, and establish long-term safety and efficacy data. Addressing these challenges is critical for integrating psilocybin into mainstream mental health care and unlocking its full therapeutic potential.
Key numbers
−12.3
Decrease in Depression Rating Scale
Mean difference on the Montgomery–Åsberg Depression Rating Scale within 43 days.
20–30 mg/70 kg
Optimal Dose
Typical dosing range for in clinical trials.
2014 to 2024
Study Inclusion Criteria
Studies included were published within this period.
Full Text
We can’t show the full text here under this license.
